Literature DB >> 30362156

Meningeal inflammation and cortical demyelination in acute multiple sclerosis.

Ryan J Bevan1, Rhian Evans1, Lauren Griffiths1, Lewis M Watkins1, Mark I Rees1, Roberta Magliozzi2,3, Ingrid Allen4, Gavin McDonnell5, Rachel Kee5, Michelle Naughton4, Denise C Fitzgerald4, Richard Reynolds3, James W Neal1, Owain W Howell1,3.   

Abstract

OBJECTIVE: Cortical gray matter (GM) pathology, involving demyelination and neurodegeneration, associated with meningeal inflammation, could be important in determining disability progression in multiple sclerosis (MS). However, we need to know more about how cortical demyelination, neurodegeneration, and meningeal inflammation contribute to pathology at early stages of MS to better predict long-term outcome.
METHODS: Tissue blocks from short disease duration MS (n = 12, median disease duration = 2 years), progressive MS (n = 21, disease duration = 25 years), non-diseased controls (n = 11), and other neurological inflammatory disease controls (n = 6) were quantitatively analyzed by immunohistochemistry, immunofluorescence, and in situ hybridization.
RESULTS: Cortical GM demyelination was extensive in some cases of acute MS (range = 1-48% of total cortical GM), and subpial lesions were the most common type (62%). The numbers of activated (CD68+ ) microglia/macrophages were increased in cases with subpial lesions, and the density of neurons was significantly reduced in acute MS normal appearing and lesion GM, compared to controls (p < 0.005). Significant meningeal inflammation and lymphoid-like structures were seen in 4 of 12 acute MS cases. The extent of meningeal inflammation correlated with microglial/macrophage activation (p < 0.05), but not the area of cortical demyelination, reflecting the finding that lymphoid-like structures were seen adjacent to GM lesions as well as areas of partially demyelinated/remyelinated, cortical GM.
INTERPRETATION: Our findings demonstrate that cortical demyelination, neuronal loss, and meningeal inflammation are notable pathological hallmarks of acute MS and support the need to identify early biomarkers of this pathology to better predict outcome. Ann Neurol 2018;84:829-842.
© 2018 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30362156     DOI: 10.1002/ana.25365

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  33 in total

1.  Longitudinally persistent cerebrospinal fluid B cells can resist treatment in multiple sclerosis.

Authors:  Ariele L Greenfield; Ravi Dandekar; Akshaya Ramesh; Erica L Eggers; Hao Wu; Sarah Laurent; William Harkin; Natalie S Pierson; Martin S Weber; Roland G Henry; Antje Bischof; Bruce Ac Cree; Stephen L Hauser; Michael R Wilson; H-Christian von Büdingen
Journal:  JCI Insight       Date:  2019-03-21

2.  No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.

Authors:  Mehrnaz Ighani; Samuel Jonas; Izlem Izbudak; Seongjin Choi; Alfonso Lema-Dopico; Jun Hua; Erin E O'Connor; Daniel M Harrison
Journal:  Mult Scler       Date:  2019-10-01       Impact factor: 6.312

3.  Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.

Authors:  Dejan Jakimovski; Murali Ramanathan; Bianca Weinstock-Guttman; Niels Bergsland; Deepa P Ramasamay; Ellen Carl; Michael G Dwyer; Robert Zivadinov
Journal:  Mult Scler       Date:  2019-02-13       Impact factor: 6.312

Review 4.  The immunology of multiple sclerosis.

Authors:  Kathrine E Attfield; Lise Torp Jensen; Max Kaufmann; Manuel A Friese; Lars Fugger
Journal:  Nat Rev Immunol       Date:  2022-05-04       Impact factor: 53.106

5.  Immunopathology of the optic nerve in multiple sclerosis.

Authors:  Laura Fernández Blanco; Manuel Marzin; Alida Leistra; Paul van der Valk; Erik Nutma; Sandra Amor
Journal:  Clin Exp Immunol       Date:  2022-08-19       Impact factor: 5.732

6.  Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury.

Authors:  Lesley A Ward; Dennis Sw Lee; Anshu Sharma; Angela Wang; Ikbel Naouar; Xianjie I Ma; Natalia Pikor; Barbara Nuesslein-Hildesheim; Valeria Ramaglia; Jennifer L Gommerman
Journal:  JCI Insight       Date:  2020-01-16

Review 7.  Diversity and Function of Glial Cell Types in Multiple Sclerosis.

Authors:  Lucas Schirmer; Dorothy P Schafer; Theresa Bartels; David H Rowitch; Peter A Calabresi
Journal:  Trends Immunol       Date:  2021-02-13       Impact factor: 16.687

8.  Structural and Clinical Correlates of a Periventricular Gradient of Neuroinflammation in Multiple Sclerosis.

Authors:  Emilie Poirion; Matteo Tonietto; François-Xavier Lejeune; Vito A G Ricigliano; Marine Boudot de la Motte; Charline Benoit; Géraldine Bera; Bertrand Kuhnast; Michel Bottlaender; Benedetta Bodini; Bruno Stankoff
Journal:  Neurology       Date:  2021-03-18       Impact factor: 9.910

Review 9.  B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies.

Authors:  Maria T Cencioni; Miriam Mattoscio; Roberta Magliozzi; Amit Bar-Or; Paolo A Muraro
Journal:  Nat Rev Neurol       Date:  2021-06-01       Impact factor: 42.937

10.  The Distributional Characteristics of Multiple Sclerosis Lesions on Quantitative Susceptibility Mapping and Their Correlation With Clinical Severity.

Authors:  Zhuoxin Guo; Liu Long; Wei Qiu; Tingting Lu; Lina Zhang; Yaqing Shu; Ke Zhang; Ling Fang; Shaoqiong Chen
Journal:  Front Neurol       Date:  2021-07-09       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.